Compare RR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | DTIL |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.2M | 123.0M |
| IPO Year | 2023 | 2019 |
| Metric | RR | DTIL |
|---|---|---|
| Price | $4.09 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 30.6M | 198.7K |
| Earning Date | 01-13-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,126,000.00 | $698,000.00 |
| Revenue This Year | $19.32 | N/A |
| Revenue Next Year | $146.31 | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $3.61 |
| 52 Week High | $7.43 | $8.82 |
| Indicator | RR | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 42.80 |
| Support Level | $3.91 | $4.61 |
| Resistance Level | $4.70 | $5.20 |
| Average True Range (ATR) | 0.45 | 0.34 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 59.79 | 41.08 |
Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.